

Dear Dr. Ma,

Re: Manuscript reference No. 61645

Please find attached a revised version of our manuscript "**Tenofovir disoproxil fumarate in patients with chronic hepatitis B: Results of a multicenter, double-blind, double-dummy, clinical trial at week 96**" which we would like to resubmit for publication in *World Journal of Clinical Cases*.

Your comments and those of the reviewer were highly insightful and enabled us to improve the quality of our manuscript. In the following pages are our point-by-point responses to each of the comments of the reviewer as well as your comments.

Revisions in the text are shown using yellow highlight for additions, and strikethrough font [example: ~~HBeAg~~] for deletions. In accordance with reviewer #1's suggestion, we have revised the title of the manuscript and the title of Table 1. We hope that the revisions in the manuscript and our accompanying responses will be sufficient to make our manuscript suitable for publication in *World Journal of Clinical Cases*.

We look forward to hearing from you at your earliest convenience.

Yours sincerely,

Dr. Jing-Hang Xu,

Address: Peking University First Hospital, Beijing100034, China.

E-mail:ddcatjh@sina.com

Responses to the comments of Reviewer #1

1. In the title of manuscript, i.e. 'Tenofovir disoproxil fumarate (Qingzhong versus Viread) in patients with chronic hepatitis B: Results of a multicenter, double-blind, double-dummy, clinical trial at week 96', it seems suggesting that this study compared the efficacy of Qingzhong versus Viread in CHB patients at week 96. However, all patients received treatment with Qingzhong 300 mg once daily from week 49 to week 96.
2. Many previous studies pointed out safety issues about kidney function and bone density. However, in this study, the adverse events in relation to kidney impairment and reductions of bone density were very uncommon. Did you have data about change in renal function (i.e. eGFR) or bone density in the study population? What your opinion or explanation for that?
3. In Table 1, the title was describe as '..... HBeAg-positive entecavir long-term cohort'. Please check that again.

Response:

1. Thank you for your kind reminder. As you said, all patients received treatment with Qingzhong 300 mg once daily from week 49 to week 96. So, we revised the

title as "Tenofovir disoproxil fumarate in patients with chronic hepatitis B: Results of a multicenter, double-blind, double-dummy, clinical trial at week 96".

2. Thanks for this very meaningful comments. We added the data on the kidney function to the revised version.

However, data about bone density during W48-W96 are not available.

3. We are very sorry for our negligence of the Table 1's title. We have corrected the title in the revised manuscript.

Responses to the comments of Science editor

1 Scientific quality: The manuscript describes a randomized controlled trial of the tenofovir disoproxil fumarate (Qingzhong versus Viread) in patients with chronic hepatitis B. The topic is within the scope of the WJG. (1) Classification: Grade C; (2) Summary of the Peer-Review Report: This manuscript is well organized and appropriately presented. The results of this study have valuable contributions to treatment of chronic hepatitis B patients with Qingzhong, a brand name of TDF, commercialized in China. However, the manuscript needs to be minor revision. The questions raised by the reviewer should be answered; and (3) Format: There are 6 tables. A total of 16 references are cited, including 2 references published in the last 3 years. There are no self-citations. 2 Language evaluation: Classification: Grade B. A language editing certificate issued by AJE was provided. 3 Academic norms and rules: The authors provided the Biostatistics Review Certificate, Clinical Trial Registration Statement, CONSORT 2010 Statement, the Institutional Review Board Approval Form, and the Written informed consent. The authors need to provide the signed Conflict-of-Interest Disclosure Form and Copyright License Agreement. No academic misconduct was found in the Bing search. 4 Supplementary comments: This is an unsolicited manuscript. The study was supported by 1 grant. The topic has not previously been published in the WJG. 5 Issues raised: (1) The "Author Contributions" section is missing. Please provide the author contributions; (2) The authors did not provide the approved grant application form(s). Please upload the approved grant application form(s) or funding agency copy of any approval document(s); and (3) The "Article Highlights" section is missing. Please add the "Article Highlights" section at the end of the main text. 6 Re-Review: Required. 7 Recommendation: Conditional acceptance.

Response:

1. We added the missing section mentioned in the comments, as follows: "Author Contributions", "Article Highlights", to the revised version of our manuscript.

- 2. We uploaded the approved grant application forms, the signed Conflict-of-Interest Disclosure Form and Copyright License Agreement.**